Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease
- 1 October 2021
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 23 (11) , 1-9
Abstract
Purpose of Review Pericarditis is a generally benign disease, although complications and/or recurrences may occur in up to 30% of cases. New evidence on the pathophysiology of the disease has accumulated in recent years. Recent Findings Recently, it has been shown that the activation of the NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is central in the pathophysiology of pericarditis. These findings derive from clinical data, an experimental animal model of acute pericarditis supporting a role for the NLRP3 inflammasome in pericarditis, and from indirect evidence of inhibitors of NLRP3 inflammasome in clinical trials. Summary Pericarditis is regarded as a stereotypical response to an acute damage of the mesothelial cells of the pericardial layers. NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1β, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.Keywords
This publication has 64 references indexed in Scilit:
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Intracellular Interleukin-1 Receptor 2 Binding Prevents Cleavage and Activity of Interleukin-1α, Controlling Necrosis-Induced Sterile InflammationImmunity, 2013
- Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart FailurePLOS ONE, 2012
- Injection-site reactions upon Kineret (anakinra) administration: experiences and explanationsRheumatology International, 2011
- Prevalence of C-Reactive Protein Elevation and Time Course of Normalization in Acute PericarditisCirculation, 2011
- Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor‐expressing cells: implications for its therapeutic actionBritish Journal of Pharmacology, 2011
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)The American Journal of Cardiology, 2010
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnnals of the Rheumatic Diseases, 2009
- Corticosteroids for Recurrent PericarditisCirculation, 2008
- Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patientsBritish Journal of Dermatology, 2005